Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
Corcept Therapeutics Inc. (CORT) – Form 144 filing discloses a proposed sale of 5,000 common shares by shareholder Joseph D. Lyon. The shares will be routed through Stifel Nicolaus & Co. on the NASDAQ with an estimated aggregate market value of $335,850 (based on the indicated $67.17 reference price). The company has 106.04 million shares outstanding, so the planned sale represents roughly 0.005 % of total shares.
The filer reports additional sales over the past three months totaling 18,527 shares for gross proceeds of $1.37 million. When combined with the proposed sale, Lyon’s total disposition for the rolling three-month window would reach 23,527 shares (~0.022 % of shares outstanding).
No purchase price was deferred; the 5,000 shares were acquired via stock-option exercise on 08/01/2025 and will be sold for cash. The filing contains the standard representation that the seller is unaware of undisclosed material adverse information and does not reference a Rule 10b5-1 plan.
Given the small size relative to the public float and absence of additional corporate disclosures, the filing appears routine and is unlikely to have a material impact on CORT’s valuation or trading dynamics.
Corcept Therapeutics (CORT) – Form 144 filing. President Sean Maduck has filed to sell 20,000 common shares through broker Stifel Nicolaus on or about 01 Aug 2025. At the 07/31/25 reference price, the sale is valued at $1.34 million. The shares were just acquired the same day via stock-option exercise; therefore the transaction is likely part of routine option monetisation.
Maduck has already disposed of 64,403 shares during the past three months for ~$4.79 million in gross proceeds. After the proposed trade, cumulative sales disclosed in the filing period reach ~84 k shares. CORT has 106.04 million shares outstanding, making the new sale ~0.02 % of outstanding stock and therefore not materially dilutive. No earnings, guidance or operational data are provided; this notice is strictly an insider-sale disclosure.
Corcept Therapeutics (CORT) – Form 4 insider activity
Sean Maduck, President of Corcept Endocrinology, exercised low-priced options and immediately sold the underlying shares pursuant to a 10b5-1 plan:
- 17 Jul 2025: Exercised 4,315 options at $5.05; sold 4,315 shares at a weighted-avg $73.4771.
- 18 Jul 2025: Exercised 473 options at $5.05; sold 473 shares at $73.4404.
Total shares sold: 4,788; gross proceeds ≈ $351k; per-share spread ≈ $68.4.
Post-trade holdings: 17,705 shares direct; 99,693 shares indirect (89,693 trust + 10,000 LLC); 56,993 vested options; 1,877 unvested RSAs.
The divestiture equals ~4 % of Maduck’s reported equity exposure and was pre-scheduled, suggesting limited informational content for the broader CORT investment thesis.